Analysts have slightly raised their price target for Myriad Genetics to approximately $7.95 from $7.77 per share. They cited modest improvements in expected profit margins and updated assumptions around discount rates.
What's in the News
- Myriad Genetics added two genes, F8 and FXN, to its Foresight Carrier Screen Universal Plus Panel. This update enhances compliance with the American College of Medical Genetics and Genomics (ACMG) recommendations for carrier screening. (Key Developments)
- The company formed a strategic collaboration with SOPHiA GENETICS to develop and provide a global liquid biopsy companion diagnostic (CDx) test. The partnership leverages advanced laboratory capabilities and a broad international network. (Key Developments)
- A study published in The Lancet Oncology highlighted the performance of Myriad’s Precise MRD test in monitoring ctDNA levels for patients with oligometastatic clear-cell renal cell carcinoma. The findings show potential to inform treatment decisions and spare patients from unnecessary therapies. (Key Developments)
- A new meta-analysis of six studies involving 3,532 adults with major depressive disorder found that availability of the GeneSight Psychotropic test led to significant improvements in both treatment response and remission rates. (Key Developments)
- Ben Wheeler has been promoted to Chief Financial Officer of Myriad Genetics, effective August 16, 2025, following more than 13 years with the company in various finance leadership roles. (Key Developments)
Valuation Changes
- Consensus Analyst Price Target has risen slightly from $7.77 to $7.95 per share.
- The discount rate increased marginally from 7.15% to 7.20%.
- The revenue growth projection edged down slightly from 4.53% to 4.52%.
- The net profit margin improved modestly from 16.15% to 16.33%.
- The future P/E ratio has risen slightly from 6.16x to 6.25x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.